Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Quantum Biopharma (QNTM) EBITDA (2019 - 2025)

Quantum Biopharma's EBITDA history spans 7 years, with the latest figure at -$2.4 million for Q4 2025.

  • On a quarterly basis, EBITDA fell 13.48% to -$2.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$25.4 million, a 128.13% decrease, with the full-year FY2025 number at -$15.3 million, up 5.17% from a year prior.
  • EBITDA hit -$2.4 million in Q4 2025 for Quantum Biopharma, up from -$4.6 million in the prior quarter.
  • Over the last five years, EBITDA for QNTM hit a ceiling of $25.3 million in Q2 2023 and a floor of -$13.2 million in Q2 2021.
  • Historically, EBITDA has averaged -$1.8 million across 5 years, with a median of -$3.3 million in 2024.
  • Biggest five-year swings in EBITDA: soared 223.56% in 2021 and later crashed 278.05% in 2024.
  • Tracing QNTM's EBITDA over 5 years: stood at -$13.2 million in 2021, then skyrocketed by 145.13% to $6.0 million in 2022, then tumbled by 220.6% to -$7.2 million in 2023, then skyrocketed by 70.99% to -$2.1 million in 2024, then fell by 13.48% to -$2.4 million in 2025.
  • Business Quant data shows EBITDA for QNTM at -$2.4 million in Q4 2025, -$4.6 million in Q3 2025, and -$9.7 million in Q2 2025.